Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1979 1
1985 2
1986 2
1988 1
1992 1
1993 1
1996 1
1997 1
1998 1
1999 1
2000 3
2001 1
2002 3
2003 2
2005 2
2006 2
2007 5
2008 2
2009 3
2010 5
2011 10
2012 11
2013 5
2014 7
2015 24
2016 15
2017 8
2018 11
2019 7
2020 25
2021 30
2022 18
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Environmental risk factors and epigenetic alternations in psoriasis.
Roszkiewicz M, Dopytalska K, Szymańska E, Jakimiuk A, Walecka I. Roszkiewicz M, et al. Among authors: szymanska e. Ann Agric Environ Med. 2020 Sep 11;27(3):335-342. doi: 10.26444/aaem/112107. Epub 2019 Nov 12. Ann Agric Environ Med. 2020. PMID: 32955211 Free article. Review.
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. Doherty G, et al. Among authors: szymanska e. J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi: 10.1093/ecco-jcc/jjx101. J Crohns Colitis. 2018. PMID: 28981623 Free article. Review.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Psoriasis in special localizations.
Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Dopytalska K, et al. Among authors: szymanska e. Reumatologia. 2018;56(6):392-398. doi: 10.5114/reum.2018.80718. Epub 2018 Dec 23. Reumatologia. 2018. PMID: 30647487 Free PMC article. Review.
Does smoking affect your skin?
Lipa K, Zając N, Owczarek W, Ciechanowicz P, Szymaǹska E, Walecka I. Lipa K, et al. Among authors: szymanska e. Postepy Dermatol Alergol. 2021 Jun;38(3):371-376. doi: 10.5114/ada.2021.103000. Epub 2021 Jan 25. Postepy Dermatol Alergol. 2021. PMID: 34377115 Free PMC article. Review.
Hidradenitis suppurativa - biologic therapy and other available treatment options.
Lipa K, Zając N, Witkowski G, Ciechanowicz P, Wiszniewski K, Szymańska E, Walecka I. Lipa K, et al. Among authors: szymanska e. Postepy Dermatol Alergol. 2023 Aug;40(4):518-528. doi: 10.5114/ada.2021.112075. Epub 2022 Jan 18. Postepy Dermatol Alergol. 2023. PMID: 37692279 Free PMC article. Review.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
205 results